2.44
0.09 (3.83%)
| Previous Close | 2.35 |
| Open | 2.25 |
| Volume | 20 |
| Avg. Volume (3M) | 219 |
| Market Cap | 1,546,830,720 |
| 52 Weeks Range | |
| Earnings Date | 10 Apr 2025 |
| Profit Margin | -203.39% |
| Operating Margin (TTM) | -127.07% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | -6.10% |
| Total Debt/Equity (MRQ) | 5.84% |
| Current Ratio (MRQ) | 3.95 |
| Operating Cash Flow (TTM) | -2.92 M |
| Levered Free Cash Flow (TTM) | 1.19 M |
| Return on Assets (TTM) | -7.35% |
| Return on Equity (TTM) | -38.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (GB) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | RELIEF THERAPEUTICS HOLDING SA | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
| ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
| BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
| IOVANCE BIOTHERAPEUTICS INC IOV | 401 M | - | - | - |
|
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.00% |
| % Held by Institutions | 23.11% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |